MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.390
-0.020
-0.45%
After Hours: 4.400 +0.01 +0.23% 19:01 08/07 EDT
OPEN
4.350
PREV CLOSE
4.410
HIGH
4.700
LOW
4.320
VOLUME
1.28M
TURNOVER
--
52 WEEK HIGH
8.35
52 WEEK LOW
1.000
MARKET CAP
39.62M
P/E (TTM)
-0.4615
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HEPA stock price target is 13.00 with a high estimate of 14.00 and a low estimate of 12.00.

EPS

HEPA News

More
Hepion Pharmaceuticals Announces First NASH Patient Dosed With CRV431 In Phase 2 'AMBITION' Clinical Trial
Benzinga · 3d ago
65 Biggest Movers From Yesterday
Gainers MOGU Inc. (NASDAQ: MOGU) shares climbed 104.8% to close at $5.92 on Tuesday.
Benzinga · 07/08 10:05
Hepion Pharma's lead candidate shows encouraging action in COVID-19 models
Nano cap Hepion Pharmaceuticals (NASDAQ:HEPA) announces positive results on lead drug CRV431 in two preclinical research models related to COVID-19. CRV431
seekingalpha · 07/07 17:09
NVAX, MFGP, RUN and TOPS among midday movers
Seeking Alpha - Article · 07/07 16:43
51 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 07/07 16:15
Mid-Morning Market Update: Markets Mixed; Paychex Tops Q4 Expectations
Following the market opening Tuesday, the Dow traded down 0.50% to 26,156.80 while the NASDAQ rose 0.43% to 10,478.83. The S&P also fell, dropping 0.05% to 3,178.27.
Benzinga · 07/07 14:21
NVAX, LVGO among premarket gainers
Seeking Alpha - Article · 07/07 12:18
Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials
Seeking Alpha - Article · 06/30 14:25

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About HEPA

Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.
More

Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.